Schizophrenia drug MP-214 tested for Long-Term safety

NCT ID NCT01626872

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at the long-term safety and tolerability of the drug MP-214 in 254 people with schizophrenia. Participants had already completed an earlier trial and continued taking MP-214 at flexible doses. The main goal was to track side effects over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MP-214 (an antipsychotic drug)
What this could lead to: If successful, this could confirm MP-214 as a safe long-term treatment option for schizophrenia.
What could go wrong: This is an extension study focused on safety, not a new treatment. The drug may still cause side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psychiatric disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Study site

Sapporo, Hokkaido, Japan
Study site

Seoul, South Korea
Study site

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.